Could a Pre-Surgery drug stop skin cancer from coming back?
NCT ID NCT04975152
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 34 times
Summary
This early-stage trial is testing whether the drug cemiplimab (Libtayo) is safe and effective when given before surgery to remove Merkel cell carcinoma or cutaneous squamous cell carcinoma. About 36 people with stage I or II disease will receive the drug every three weeks for up to nine cycles before their operation. Researchers are primarily looking at side effects and also tracking how long participants stay cancer-free after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MERKEL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cemiplimab (Libtayo)
What this could lead to
If successful, this could show that giving cemiplimab before surgery helps reduce the risk of cancer returning in people with these skin cancers.
What could go wrong
This is a very early phase 1 trial with only 36 participants, so results may not apply to everyone. Side effects from cemiplimab can include immune-related reactions.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.